{"a":[{"_":"AZ's blood pressure newcomer Baxfendy fails to meet cost-effectiveness bar, ICER says","$":{"href":"/pharma/azs-baxfendy-not-worth-its-price-tag-icer-says","hreflang":"en"}}]}

RegulatoryBaxfendyNegative

AI Analysis

Summary

AstraZeneca's newly approved blood pressure drug Baxfendy failed to meet ICER's cost-effectiveness threshold, according to the U.S. drug price watchdog.

Outcome Details

ICER determined the drug does not meet cost-effectiveness standards relative to its price

Importance:6/10

Sentiment:

-0.60

pricingcost-effectivenessICERblood pressurenewly approved

Related Companies

$AZN

Read the original article

Published by FiercePharma on August 13, 2026 11:10 AM

Read Original